ST-246 Days 1 - 3 + ST-246 Days 11 - 13
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Orthopoxviral Disease
Conditions
Orthopoxviral Disease, Smallpox, Monkey Pox
Trial Timeline
Aug 1, 2008 → Oct 1, 2008
NCT ID
NCT00728689About ST-246 Days 1 - 3 + ST-246 Days 11 - 13
ST-246 Days 1 - 3 + ST-246 Days 11 - 13 is a phase 1 stage product being developed by SIGA Technologies for Orthopoxviral Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00728689. Target conditions include Orthopoxviral Disease, Smallpox, Monkey Pox.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00728689 | Phase 1 | Completed |
Competing Products
1 competing product in Orthopoxviral Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ST-246 400 mg + ST-246 600 mg + Placebo | SIGA Technologies | Phase 2 | 44 |
Other Products from SIGA Technologies
Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable TabletApproved
77
TpoxxApproved
77
Tecovirimat Oral Capsule + Placebo for Tecovirimat + Tecovirimat Oral Capsule (Open Label)Phase 3
69
tecovirimatPhase 3
69
TPOXXPhase 3
69